View Older Stories View More Recent Stories

May 17, 2021 04:10PM Concert Pharma (CNCE) Announces Sale of VX-561 Milestones to Vertex (VRTX) for $32 Million
May 17, 2021 04:01PM Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million
May 12, 2021 11:01AM Vertex (VRTX) and CRISPR Therapeutics (CRSP) to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies at EHA
May 12, 2021 11:00AM Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Vi
May 10, 2021 09:01AM Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
Apr 29, 2021 04:01PM Vertex Reports First-Quarter 2021 Financial Results
Apr 26, 2021 08:33AM Vertex (VRTX) and CRISPR Therapeutics (CRSP) Announce PRIME Designation Granted by EMA to CTX001 for Transfusion-Dependent Beta Thalassemia
Apr 26, 2021 08:30AM Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Apr 26, 2021 07:29AM Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development
Apr 22, 2021 08:07AM Vertex Pharma (VRTX) and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
Apr 22, 2021 08:00AM Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
Apr 20, 2021 07:39AM Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia
Apr 20, 2021 07:15AM Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
Apr 19, 2021 09:01AM Vertex to Announce First-Quarter 2021 Financial Results on April 29
Mar 10, 2021 07:55AM Vertex Pharma (VRTX) Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
Mar 10, 2021 07:55AM Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
Feb 24, 2021 09:01AM  Vertex to Present at the Cowen Health Care Conference on March 2
Feb 1, 2021 04:01PM Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
Jan 28, 2021 04:37PM Vertex Pharma (VRTX) Announces FDA Clearance of IND Application for VX-880
Jan 28, 2021 04:11PM Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
Jan 26, 2021 08:31AM Vertex Pharma (VRTX) Announces U.S. FDA Acceptance of sNDA for TRIKAFTA in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
Jan 26, 2021 08:30AM Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certai
Jan 22, 2021 09:01AM Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
Dec 28, 2020 08:08AM Vertex Pharma (VRTX) Announces New Drug Submission for TRIKAFTA in Canada to Treat CF
Dec 28, 2020 08:04AM Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada
Dec 22, 2020 08:30AM Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases
Dec 21, 2020 02:31PM Vertex (VRTX) Announces FDA Approvals of TRIKAFTA, SYMDEKO, and KALYDECO for Use in People With CF With Certain Rare Mutations
Dec 21, 2020 02:30PM Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With
Dec 5, 2020 12:30PM CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publicati
Dec 1, 2020 09:00AM CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Edi
Nov 27, 2020 06:15AM Vertex (VRTX) Announces European Commission Approval for SYMKEVI With KALYDECO for Eligible Children With Cystic Fibrosis Ages 6-11 Years
Nov 27, 2020 03:00AM Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
Nov 13, 2020 04:01PM Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation
Nov 12, 2020 04:01PM Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19
Nov 5, 2020 05:58AM Vertex Pharma (VRTX) Reports European Commission Approval of Label Extension for KALYDECO (ivacaftor)
Nov 5, 2020 04:00AM Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age
Nov 4, 2020 09:15AM CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
Oct 29, 2020 04:01PM Vertex Reports Third-Quarter 2020 Financial Results
Oct 19, 2020 04:01PM Vertex to Announce Third-Quarter 2020 Financial Results on October 29
Oct 14, 2020 04:49PM Vertex Pharma (VRTX) has decided to stop dosing in trial and will discontinue development of VX-814
Oct 14, 2020 04:30PM Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency
Sep 25, 2020 08:03AM Vertex Pharma (VRTX) Announces FDA Approves KALYDECO as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
Sep 25, 2020 08:00AM FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
Sep 24, 2020 05:25AM Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators
Sep 22, 2020 09:01AM CRISPR Therapeutics (CRSP), Vertex Pharmaceuticals (VRTX) Announce PRIME Designation Granted by EMA to CTX001 for Treatment of Sickle Cell Disease
Sep 22, 2020 09:00AM CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
Sep 10, 2020 09:04AM Vertex Pharma (VRTX) Announces Positive Phase 3 Study for TRIKAFTA in Children Ages 6-11 Years With CF to Support Submissions for Global Regulatory Approvals
Sep 10, 2020 09:00AM Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Ap
Sep 10, 2020 03:57AM The Vertex Foundation Announces €1 Million Donation to Ronald McDonald House Charities at the New Children’s Hospital in Ireland
Sep 1, 2020 09:03AM Vertex Pharma (VRTX) Announces FDA Accepts its sNDA for TRIKAFTA, SYMDEKO and KALYDECO for Additional CFTR Mutations
View More Recent Stories View Older Stories